Jonathan Rigby has a breadth of industry knowledge and product experience spanning three decades. Currently serving as CEO of Sernova Biotherapeutics (TSX: SVA) he is advancing a novel cell therapy treatment for type 1 diabetes. Having previously served as President and Chief Executive Officer of Revolo Biotherapeutics, where he took the company through multiple financings and two phase 2 clinical trials, as well as Chairman and Chief Business Officer of BIOS Acquisition Corporation (Nasdaq: BIOS), with an oversold IPO. He served as the Chief Executive Officer of SteadyMed Therapeutics (Nasdaq: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (Nasdaq: UTHR), and was cofounder of Zogenix (Nasdaq: ZGNX), which was acquired by UCB for $2 Billion after completing a Nasdaq listing and two drug product approvals.
In addition, Mr. Rigby currently serves as the Chair of Exciting Instruments, UK, and on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (Nasdaq: ONCY) and IM Therapeutics, which is developing therapies for T1D. He is a past board member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D, and was formerly on the board of Xeris Pharmaceuticals (Nasdaq: XERS), which developed and commercializes a therapy to treat severe hypoglycemia in patients with T1D. Earlier in his career, Mr. Rigby held roles at Merck and BMS. He holds a degree in biological sciences from the University of Sheffield, UK, and has a master of business administration degree from the University of Portsmouth, UK.
Back to Team